Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
I'm going down to the AGM from Scotland (anybody else?) and trying to temper my excitement but really looking forward to it and especially meeting members of the BOD, hearing what they have to say and how they say it.
Cheers
JT
Bella, thank you for your longstanding input with regard to the market, logistics, exhibitions etc. All much-appreciated info' and always a reasoned, intelligent voice amongst the high volume of bickering and playground antics from the majority.
Holding long and strong.
Cheers
JT
Here was me Googling it to check it wasn't some English version of Alastair. Yeah, I've been here long enough to know Abacta. I'll shut up now but hey, it did get a few rec's, so might still have been worth it to some.
Cheers
JT
Guys, sorry to sound dull but do you not think it's a bit disrespectful to Dr Alistair Smith to call him Alan?
The status of the man, current and potential, should not be mocked in my opinion.
Please give him the respect he so richly deserves.
Cheers
JT
Can't sleep as we're just back from a cruise and I'm still jet-lagged. I don't know why I'm putting this out there, but I will anyway.
I'm thinking, seeing how Avacta is aiming/hoping to keep AVA6000 in-house, that we may see a licensing deal for AVA3996 (or another pre|CISION candidate) on or before Science Day. If it was me doing the deal, I'd be looking for a very large up-front payment, say £200m, in lieu of undisclosed, lower milestone payments and royalties (5%?) for this first licence, thereby setting the tone for subsequent licencing deals, as far as up-front payments are concerned. Subsequent deals can then incorporate a higher level of milestone payments and royalties (10%?). The up-front payments will then hopefully provide the vital cash flow to progress AVA6000 through P2 and keep any buy-out attempts at bay. A move to (and raise on) Nasdaq, when the timing is right, could possibly fund TMAC into clinic down the line.
I'm sure we all know and accept that we cannot possibly bring AVA6000 to market ourselves as we do not have the infrastructure, knowledge or experience, yet alone the time and resources. I think the only way we can keep it in-house (ish) is a partnership with one of the big boys.
A takeover of TX only, could be extremely complicated as Affimers from DX along with pre|CISION from TX combine to make up TMAC, the Holy Grail. How does any buyer get around that complication, possibly licence Affimers from DX? There are also the various existing licencing deals with Point, Daewong etc. who may be considered competitors of the buyer - complicated again?
There are too many shots at goal here for one company to take the lot. I just can't see Dr Smith wanting to sell up his life's work. He's a rich man already, maybe just on paper at the moment, who knows? Regardless, if this is as good as we (mostly) believe, he will be an extremely rich man and deserves every penny he gets.
No, I think he will want to take pre|CISION, Affimers and TMAC forward with the Avacta name behind it and I hope he does and that he will be rewarded with a Nobel Prize or at least Knighted for Services to Science.
Extremely exciting week ahead. I'm confident the superb Avacta team will deliver and I can't wait to see the presentation video on Friday.
These are just musings and should not be taken seriously so you have my permission to mock at will
Apologies for any bad spelling, punctuation or diction, I'm tired.
Cheers
JT
Yeah, graet post Starbright.
Paul, I cannot see any discounted raise happening. However if, and it's a big if, there is to be a raise, I can only see it happening at a good premium to the prevailing share price.
I don't think Avacta can keep a hold of the therapeutic division, so to me, it's a moot point anyway.
Cheers
JT
Good post Runner-Runner. I completely agree. This board has a number of very childish posters. It's not Facebook but is treated as if it is by many. There's not much chance of the uncalled-for hatred/dislike for Wyndrum abating anytime soon but that was a good attempt never-the-less. Please filter him if you don't like what he says and stop spoiling this board.
Cheers
JT
I assume it will be possible to sell enough shares in your fully subscribed ISA close to or on the 2nd of November to purchase the open offer shares. Hopefully/surely, there will be an uplift in the SP by then. If so you will then be able to buy the open offer shares for 95p but will have sold fewer shares at say 120p to fund the purchase. This will result in a net gain in the number of shares in your ISA.
This is how I'm thinking of doing it in all accounts and SIPP as I'm not allowed to buy any more, says she who must be obeyed. Feel free to correct me if I'm mistaken.
Cheers
JT
Hi Bottom_feeder
Most of your questions imply that you have carried out very little research. May I politely suggest that you check out the Avacta website, where all of your questions and more, will be answered in full. Good luck.
Cheers
JT
I'm heavilly invested here, which I have been building up to since april 2020. Way more than I ever thought possible but it's just the way my finances have turned out. It wouldn't ruin my retirement but it would be a sore burden to bear if our (beloved) Avacta failed to deliver on the inference of success that, I assume, most of us believe in.
I firmly believe that we will achieve huge success in both the theraputics and diagnostics divisions, by turning what was a small, pre-clinical, British Biotech, into a worldwide Pharma giant. I also believe that Dr Smith has now got the bones of a team capable of achieving this.
I'm scared to tell too many people about this for fear of losing friend's hard earned money if failure ensues, despite my optimism and belief. On the flip side, if we make millions, how does one cope with - "you should have told me, I would have invested"?
My wife is telling me to keep quiet.
So, so excited to be an Avacta shareholder and hope that we all reap the rewards of our investments but most of all, that Dr Smith realises his dreams and goals for cancer sufferers worldwide.
P.S The wife's away and I've had a couple o mid-week glasses, so hence the soppy (but heartfelt) post.
Cheers
JT
Hi all. I've been investing now for around 3 years and EML was my first ever buy after reading an article in the Sunday Mail. I'm in 3 shares only, including EML. I'm about to put some money into my SIPP and am looking to put £50k of that into EML as I'm absolutely confident it will perform extremely well. I feel this is a good time due to the, hopefully, forthcoming issuance of the ESIA. However we are obviously in a strong bear market which may continue for a long time and we've seen the share price fall a fair bit from it's recent high on no news. What are your opinions on timing this investment and is it best to do it in multiple tranches of say £5k or £10k, or all at once (if possible)?
Appreciate any genuine opinions.
Cheers
JT
Sorcerer and Ophidian - very interesting.
Let's say, in the dose expansion phase, they were to target STC(Sarcoma) and Salivary Gland cancer, being the second and third top tumour types, by FAPa concentration, on that slide and then let's assume that at the end of the trial AVA6000 is found to be extremely successful in treating these two types of cancer. I think it would be better to also prove success in targeting a cancer such as Ovarian that has less concentration of FAPa. This, to me, would show that Prodox has the potential to successfully treat a broader range of cancer types with a broader concentration of FAPa in the TME, meaning we have a more valuable asset. Could that be the thinking behind the selecting of these cancer types for the dose expansion Phase 1b?
Cheers
JT
Hi Templar, to look at this mornings RNS statement from a more optimistic viewpoint, rather that calling it a 'profits warning', which I feel is definitely not the intention, could it not be conceivable that the temporary UK sales suspension having no 'material impact' on year end results might be down to the fact that sales outwith the UK are going so well that current UK sales are fairly insignificant by contrast. It would certainly be nice if this was the case and it probably isn't but who knows? Certainly not me.
By the way, it's good to see that NDN, Rorkes, AgentB and Wyndrum haven't buckled under the immense pressure from the children on here. Keep it up guys and gal.
£10k ISA top up this morning at 110.38p so i'm happy and holding long term.
Cheers
JT